Company: LNAI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001731122-25-000765
Chunk: 142

Company: Lunai Bioworks Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 142
---
 dedicated to the
development of early cancer detection blood tests and expects to develop partnerships with third-party laboratories across the United
Kingdom, the Netherlands and the rest of Europe and will also expand to the United States. Renovaro Cube is focused on developing diagnostic
tests and test kits that would analyze samples derived from non-invasive liquid biopsy samples and intends to perform these tests from
Renovaro’s dedicated fully certified service laboratory and engage third-party laboratories to perform these tests for end-users.

For this purpose, Renovaro Cube
has developed an AI platform that aims to leverage expertise in both biological and computational sciences and to go beyond traditional
tumor signals by detecting the body’s early warning signs of cancer. Renovaro Cube’s goal is to provide accurate and reliable
tests that can aid in the early diagnosis and treatment of cancer. Renovaro Cube’s AI technology is created to detect a wide range
of biological signs to enhance the accuracy and sensitivity of early cancer detection and, thereby, enable earlier intervention and potentially
improved patient outcomes.

Renovaro Cube’s AI technology
aims to address three critical facets of medical needs within the domain of cancer diagnosis (as illustrated below):

    ●
    type-specific cancer detection;

    ●
    pan-cancer detection; and

    ●
    patient stratification.

28

Moreover, the versatility of Renovaro
Cube’s AI technology extends to encompass the realm of rare cancers, including cases such as cancer of unknown primary.

Leveraging DNA methylation data,
Renovaro Cube has identified and validated biomarker panels tailored for the detection of a wide range of cancers, including bladder,
breast, colon, prostate, thyroid, head and neck, liver, kidney and lung cancer.

The foundational architecture of
Renovaro Cube’s AI technology is engineered to facilitate comprehensive pan-cancer analysis through its extensive record of informative
biomarkers discovered across a diverse array of cancer types. This comprehensive repository empowers Renovaro Cube’s AI technology
to swiftly cross-reference biomarkers and explore molecular commonalities and distinctions that span multiple tumor categories.

For example, the capabilities of
Renovaro Cube’s AI technology have unearthed biomarkers capable of pinpointing a specific subgroup of thyroid cancer patients characterized
by a distinct genomic alteration, the neurotrophic tyrosine receptor kinase (“NTRK”) gene fusion. Identification of these
NTRK-positive patients provides an actionable therapeutic target.

Uses of Renovaro Cube’s AI Technology

Renovaro Cube